QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-briacell-therapeutics-maintains-18-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates BriaCell Therapeutics (NASDAQ:BCTX) with a Buy and maintains $18 pri...

Core News & Articles

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage b...

 why-is-breast-cancer-focused-briacell-therapeutics-stock-trading-over-100-on-wednesday

BriaCell Therapeutics stock rises on positive Phase 2 trial results showing improved survival in late-stage metastatic breast c...

Core News & Articles

BCTX: 143% | BriaCell Announces Phase 2 Data Showing Median Overall Survival Of 15.6 Months In Bria-IMT Study For Metastatic Br...

 briacell-therapeutics-says-received-positive-feedback-from-its-pre-investigational-new-drug-application-meeting-with-fda-for-bria-pros-in-prostate-cancer

As a result of the Pre-IND meeting, FDA waived the animal toxicology and animal pharmacokinetic (PK) studies requirement for op...

 briacell-reports-extended-progression-free-survival-to-91-months-in-adc-resistant-metastatic-breast-cancer-patient-top-responder-continues-bria-imt-treatment-in-phase-2-study

Previously Reported Significant Reduction Of "Eye-Bulging" Tumor; Patient Had Failed 8 Prior Regimens

 hc-wainwright--co-reiterates-buy-on-briacell-therapeutics-maintains-18-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates BriaCell Therapeutics (NASDAQ:BCTX) with a Buy and maintains $18 pri...

 briacell-presents-clinical-efficacy-data-of-randomized-phase-2-study-evaluating-bria-imt-in-patients-with-advanced-metastatic-breast-cancer-at-asco-2024

BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literatureBria-IMT™ PFS...

Core News & Articles

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage b...

 briacell-doubles-progression-free-survival-and-reports-clinical-data-of-bria-imt-asco-2024

83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS m...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION